MCMDC2: A Potential Drug Target for Cancer and Other Health Issues
MCMDC2: A Potential Drug Target for Cancer and Other Health Issues
MCMDC2, also known as Minichromosome maintenance domain-containing protein 2 (ISOform A), is a protein that plays a crucial role in the maintenance of chromosomal stability during cell division. It is a key component of the minichromosome, which is a small subunit of the eukaryotic chromosome that is responsible for ensuring the proper separation of chromosomes during cell division. MCMDC2 is a highly conserved protein that is found in all eukaryotic cells, making it an attractive target for drug development.
MCMDC2 was first identified in the 1990s using genetic screening techniques. It is a 16kDa protein that contains a unique domains: a 9kDa N-terminal domain, a 3.5kDa transmembrane domain, and a 3.5kDa C-terminal domain. The N-terminal domain is rich in amino acids that are involved in protein-protein interactions, while the C-terminal domain contains a unique glycine residue that is known to be involved in protein-DNA interactions.
One of the most significant features of MCMDC2 is its role in the maintenance of chromosomal stability. During cell division, the minichromosome is replicated and then separated to ensure that each new cell receives an accurate copy of the genetic information. MCMDC2 is involved in the proper attachment and detachment of the minichromosome to the microtubules of the spindle, as well as the subsequent separation of the minichromosome from the nuclear envelope during mitosis or meiosis.
MCMDC2 has also been shown to play a role in the regulation of gene expression. It has been shown to interact with various transcription factors, including TFAP2, which is a known regulator of gene expression. MCMDC2 has been shown to physically interact with TFAP2 and to play a role in the regulation of TFAP2-mediated gene expression.
In addition to its role in the regulation of gene expression, MCMDC2 has also been shown to be involved in the development and maintenance of cancer. It has been shown to be involved in the regulation of cell cycle progression, and has been implicated in the development of various types of cancer. For example, MCMDC2 has been shown to be involved in the regulation of the growth and survival of cancer cells, and has been shown to be a potential drug target for cancer therapy.
MCMDC2 has also been shown to play a role in the regulation of cellular processes that are important for human health, such as fetal development and regeneration. It has been shown to be involved in the regulation of cell proliferation, and has been implicated in the development and maintenance of various types of cancer, including breast cancer.
Given its role in the maintenance of chromosomal stability and its involvement in the regulation of gene expression and cellular processes, MCMDC2 is an attractive target for drug development. Many small molecules have been shown to interact with MCMDC2, and there is growing interest in the use of these compounds as potential therapeutic agents.
One of the most promising compounds that has been shown to interact with MCMDC2 is the drugletisin A, which is a small molecule that has been shown to interact with MCMDC2 and to play a role in the regulation of gene expression. The results of these studies suggest that drugletisin A may be an effective therapeutic agent for the treatment of various types of cancer.
Another compound that has shown promise in the targeting of MCMDC2 is the drug gabapentin, which is an inhibitor of the protein p21 (TOR). The results of these studies suggest that gabapentin may be an effective therapeutic agent for the treatment
Protein Name: Minichromosome Maintenance Domain Containing 2
Functions: Plays an important role in meiotic recombination and associated DNA double-strand break repair
The "MCMDC2 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about MCMDC2 comprehensively, including but not limited to:
• general information;
• protein structure and compound binding;
• protein biological mechanisms;
• its importance;
• the target screening and validation;
• expression level;
• disease relevance;
• drug resistance;
• related combination drugs;
• pharmacochemistry experiments;
• related patent analysis;
• advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai
More Common Targets
MCOLN1 | MCOLN2 | MCOLN3 | MCPH1 | MCPH1-AS1 | MCPH1-DT | MCRIP1 | MCRIP2 | MCRS1 | MCTP1 | MCTP2 | MCTS1 | MCTS2 | MCU | MCUB | MCUR1 | MDC1 | MDFI | MDFIC | MDGA1 | MDGA2 | MDH1 | MDH1B | MDH2 | MDK | MDM1 | MDM2 | MDM4 | MDN1 | MDS2 | ME1 | ME2 | ME3 | MEA1 | MEAF6 | MEAF6P1 | MEAK7 | Mechanoelectrical transducer (MET) channel | Mechanosensitive Ion Channel | MECOM | MECOM-AS1 | MeCP1 histone deacetylase (HDAC) complex | MECP2 | MECR | MED1 | MED10 | MED11 | MED12 | MED12L | MED13 | MED13L | MED14 | MED14P1 | MED15 | MED15P8 | MED16 | MED17 | MED18 | MED19 | MED20 | MED21 | MED22 | MED23 | MED24 | MED25 | MED26 | MED27 | MED28 | MED29 | MED30 | MED31 | MED4 | MED4-AS1 | MED6 | MED7 | MED8 | MED9 | MEDAG | Mediator Complex | Mediator of RNA Polymerase II Transcription | MEF2A | MEF2B | MEF2C | MEF2C-AS1 | MEF2C-AS2 | MEF2D | MEFV | MEG3 | MEG8 | MEG9 | MEGF10 | MEGF11 | MEGF6 | MEGF8 | MEGF9 | MEI1 | MEI4 | MEIG1 | MEIKIN | MEIOB
